Analyzing ACADIA Pharmaceuticals Inc. (ACAD) After Recent Trading Activity


In a filing, ACADIA Pharmaceuticals Inc. revealed its EVP, Chief Financial Officer Schneyer Mark C. unloaded Company’s shares for reported $0.29 million on Aug 21. In the deal valued at $29.00 per share,10,000 shares were sold. As a result of this transaction, Schneyer Mark C. now holds 15,682 shares worth roughly $ 0.44 million.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Then, DAVIS STEPHEN sold 100,000 shares, generating $3,004,350 in total proceeds. Upon selling the shares at $30.04, the CEO now owns 36,695 shares.

Before that, DAVIS STEPHEN sold 55,104 shares. ACADIA Pharmaceuticals Inc. shares valued at $1,380,449 were divested by the CEO at a price of $25.05 per share. As a result of the transaction, DAVIS STEPHEN now holds 36,695 shares, worth roughly $1.02 million.

Guggenheim upgraded its ACADIA Pharmaceuticals Inc. [ACAD] rating to a Buy from a a Neutral in a research note published on Friday. PT values the company’s stock at a premium of -26.32 to its Friday closing price.

Price Performance Review of ACAD

On Friday, ACADIA Pharmaceuticals Inc. [NASDAQ:ACAD] saw its stock jump 2.85% to $27.79. On the same session, the stock had its day’s lowest price of $27.17, but rose to a high of $27.855. Over the last five days, the stock has lost -2.83%. ACADIA Pharmaceuticals Inc. shares have risen nearly 74.56% since the year began. Nevertheless, the stocks have risen 69.14% over the past one year. While a 52-week high of $33.99 was reached on 07/18/23, a 52-week low of $13.73 was recorded on 01/03/23. SMA at 50 days reached $27.68, while 200 days put it at $21.43. A total of 0.93 million shares were traded, compared to the trading of 1.12 million shares in the previous session.

Levels Of Support And Resistance For ACAD Stock

The 24-hour chart illustrates a support level at 27.36, which if violated will result in even more drops to 26.92. On the upside, there is a resistance level at 28.04. A further resistance level may holdings at 28.29. The Relative Strength Index (RSI) on the 14-day chart is 48.45, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.16, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 72.54%. Stochastics %K at 16.62% indicates the stock is a buying.

How much short interest is there in ACADIA Pharmaceuticals Inc.?

A steep rise in short interest was recorded in ACADIA Pharmaceuticals Inc. stocks on Aug 14, 2023, growing by 0.99 million shares to a total of 9.77 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 8.78 million shares. There was a rise of 10.13%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 7.99% of the overall stock float, the days-to-cover ratio (short ratio) rose to 5.18.

ACADIA Pharmaceuticals Inc. [ACAD] – Who Are The Largest Shareholders?

In filings from Baker Bros. Advisors LP, it is revealed that the company now owns 42,864,612 shares, or roughly 26.36% of the outstanding ACAD shares. In other words, the investor’s shares have risen by 926,126 from its previous 13-F filing of 41938486.0. Additionally, The Vanguard Group, Inc. increased 1.22% of its stake after which the total value it holdings stand at $395,107,751, while RTW Investments LP added 18.69% of its stake to hold $286.06 million in the firm. Over the last quarter, BlackRock Fund Advisors purchased 187,112 shares of ACADIA Pharmaceuticals Inc., while EcoR1 Capital, LLC bought 0 shares. At present, T. Rowe Price Associates, Inc. is holding 5,827,143 shares valued at $170.39 million. SSgA Funds Management, Inc. owned 5,420,318 shares of the company at the time of its most recent 13F filing, worth $158.49 million.

However, 17 analysts have rated ACAD stock as an Overweight in their predictions for 2023.


Please enter your comment!
Please enter your name here